Drugs in focus: proton pump inhibitors

Orel, Rok; Benninga, Marc A.; Broekaert, Ilse J.; Gottrand, fréderic; Papadopoulou, Alexandra; Ribes-Koninckx, Carmen; Thomson, Mike; Wilschanski, Michael; Thapar, Nikhil

Type de document :

Article dans une revue scientifique: Article original

DOI :

10.1097/MPG.0000000000003063

PMID :

33847286

URL permanente :

http://hdl.handle.net/20.500.12210/40476

Titre :

Drugs in focus: proton pump inhibitors

Auteur(s) :

Orel, Rok [Auteur]
Benninga, Marc A. [Auteur]
Broekaert, Ilse J. [Auteur]
Gottrand, fréderic [Auteur]

Papadopoulou, Alexandra [Auteur]
Ribes-Koninckx, Carmen [Auteur]
Thomson, Mike [Auteur]
Wilschanski, Michael [Auteur]
Thapar, Nikhil [Auteur]

Titre de la revue :

Journal of pediatric gastroenterology and nutrition

Nom court de la revue :

J Pediatr Gastroenterol Nutr

Numéro :

Pagination :

645-653

Date de publication :

2021-05-01

ISSN :

1536-4801

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Proton pump inhibitors (PPIs) are amongst the most commonly prescribed drugs in infants and children with the last decades witnessing a dramatic rise in their utilization. Although PPIs are clearly effective when used ...
Lire la suite >Proton pump inhibitors (PPIs) are amongst the most commonly prescribed drugs in infants and children with the last decades witnessing a dramatic rise in their utilization. Although PPIs are clearly effective when used appropriately and have been regarded as safe drugs, there is growing evidence regarding their potential adverse effects. Although, largely based on adult data it is clear that many of these are also relevant to pediatrics. PPI use potentially affects gastrointestinal microbiota composition and function, decreases defence against pathogens resulting in increased risk for infections, interferes with absorption of minerals and vitamins leading to specific deficiencies and increased risk for bone fractures as well as interferes with protein digestion resulting in increased risk of sensitization to allergens and development of allergic diseases and eosinophilic esophagitis. An association with gastric, liver and pancreatic cancer has also been inferred from adult data but is tenuous and causation is not proven. Overall, evidence for these adverse events is patchy and not always compelling. Overall, the use of PPIs, for selected indications with a good evidence base, has significant potential benefit but carries more caution in infants and children. Pediatricians should be aware of the concerns regarding the potential adverse events associated with their use.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
Inserm
Université de Lille

Collections :

Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2021-07-06T12:44:27Z

Numéro de version	Lien	Date de modification
2	20.500.12210/40476	2024-03-04T11:12:21Z
1	20.500.12210/40476.1*	2021-07-06T12:44:27Z

Drugs in focus: proton pump inhibitors

BibTeX

CSV

Excel

RIS

Information

Historique des modifications

Drugs in focus: proton pump inhibitors BibTeX CSV Excel RIS

Information

Historique des modifications

Drugs in focus: proton pump inhibitors

BibTeX

CSV

Excel

RIS